Neurocrine Biosciences (NBIX) Operating Expenses (2010 - 2026)

Neurocrine Biosciences' Operating Expenses history runs 17 years deep, the most recent figure standing at $621.1 million for Q1 2026.

• Quarterly Operating Expenses rose 13.13% year-over-year to $621.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 billion (up 20.63% YoY) and the FY2025 annual result came in at $2.2 billion, up 25.58% from the prior year.
• Operating Expenses was $621.1 million for Q1 2026 at Neurocrine Biosciences, up from $594.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $621.1 million in Q1 2026 and bottomed at $300.1 million in Q3 2022.
• A 5-year average of $442.5 million and a median of $438.3 million in 2024 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2023 — Operating Expenses soared 73.85% — and 2024, when it slipped 22.18%.
• Neurocrine Biosciences' Operating Expenses stood at $308.6 million in 2022, then gained by 18.24% to $364.9 million in 2023, then soared by 33.1% to $485.7 million in 2024, then increased by 22.42% to $594.6 million in 2025, then increased by 4.46% to $621.1 million in 2026.
• Business Quant data shows NBIX's Operating Expenses at $621.1 million in Q1 2026, $594.6 million in Q4 2025, and $555.9 million in Q3 2025.